Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
Vázquez, Ivonne (Institut Hospital del Mar d'Investigacions Mèdiques)
Papaleo, Natalia Florencia (Institut Hospital del Mar d'Investigacions Mèdiques)
Garcia, Eugenia (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques)
Salar Silvestre, Antonio (Institut Hospital del Mar d'Investigacions Mèdiques)
Hernandez-Llodrà, Silvia (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut)
Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques)
Colomo, Luis (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0. 51 p = 0. 02) and IPI (hazard ratio 1. 67 p < 0. 005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas.
Ajuts:	Ministerio de Ciencia e Innovación RD08-2-0035 Instituto de Salud Carlos III PI17/313
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	MYC rearrangement ; LMO2 ; Large B-cell lymphoma ; Immunohistochemistry
Publicat a:	Cancers, Vol. 12 (april 2020) , ISSN 2072-6694

DOI: 10.3390/cancers12040884
PMID: 32260556

12 p, 1.6 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats